NicOx   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Sophia Antipolis France (1996)

Organization Overview

First Clinical Trial
2003
NCT01256775
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NicOx Inc. | Nicox Ophthalmics, Inc | Nicox Ophthalmics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (4)

Key: NicOx (3) Acquired (1)

ac-170 (8 trials)

latanoprost (xalatan) (4 trials)

naproxen (naprosyn) (9 trials)

ncx 470 (2 trials)

Drugs in Phase 2 Trials (6)

Key: NicOx (4) Acquired (2)

bimatoprost (lumigan) (1 trial)

carrageenan (1 trial)

cellulose (1 trial)

cetirizine (zyrtec) (1 trial)

fluticasone (cutivate) (3 trials)

nitroaspirin (1 trial)

Drugs in Phase 1 Trials (4)

Key: NicOx (2) Acquired (2)

furosemide (lasix) (1 trial)

hypromelloses (1 trial)

ibuprofen (motrin) (1 trial)

olopatadine (patanol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arterial Occlusive Diseases (Phase 2)

Blepharitis (Phase 2)

Conjunctivitis (Phase 2)

Essential Hypertension (Phase 1)

Glaucoma (Phase 3)

Glaucoma, Open-Angle (Phase 3)

Hypertension (Phase 3)

Intermittent Claudication (Phase 2)

Liver Diseases (Phase 1)

Ocular Hypertension (Phase 3)

Osteoarthritis (Phase 3)

Osteoarthritis, Hip (Phase 3)

Osteoarthritis, Knee (Phase 3)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 26
  • # of Trial APIs: 14